Back to School: How biopharma can reboot drug development. Access exclusive analysis here

1016 Trax
BioCentury & Getty Images

Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

Oct 17, 2020 | 2:46 AM GMT

Luciano Rossetti will retire at year-end from Merck KGaA (Xetra:MRK) after a six-year tenure as global head of R&D for the healthcare business sector. Rossetti’s successors are Danny Bar-Zohar, who

Read the full 550 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers